John Ellerton
About
John Ellerton is a scholar working on Oncology, Surgery and Molecular Biology.
According to data from OpenAlex, John Ellerton has authored 29 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in John Ellerton's work include Bladder and Urothelial Cancer Treatments (9 papers), Urinary and Genital Oncology Studies (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). John Ellerton is often cited by papers focused on Bladder and Urothelial Cancer Treatments (9 papers), Urinary and Genital Oncology Studies (9 papers) and Cancer Immunotherapy and Biomarkers (7 papers). John Ellerton collaborates with scholars based in United States, Belgium and South Korea. John Ellerton's co-authors include Charles A. Schiffer, James F. Holland, Jimmie C. Holland, Carlos M. DeCastro, Richard A. Larson, Rosalie Odchimar-Reissig, Bayard L. Powell, Erin P. Demakos, Alice B. Kornblith and Lewis R. Silverman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
John Ellerton
29 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| John Ellerton United States | 18 | 1.4k | 1.4k | 1.2k | 493 | 429 | 29 | 3.3k | ||
| Karel A. Dicke United States | 32 | 1.3k 1.0× | 2.1k 1.5× | 634 0.5× | 281 0.6× | 489 1.1× | 108 | 3.5k | ||
| Hani Hassoun United States | 32 | 1.2k 0.9× | 1.6k 1.2× | 2.0k 1.7× | 189 0.4× | 574 1.3× | 160 | 3.7k | ||
| Stig Lenhoff Sweden | 26 | 1.0k 0.8× | 2.0k 1.5× | 877 0.7× | 151 0.3× | 365 0.9× | 87 | 2.7k | ||
| Stephen H. Petersdorf United States | 29 | 1.7k 1.2× | 2.6k 1.9× | 1.2k 1.0× | 182 0.4× | 769 1.8× | 78 | 4.7k | ||
| Ajay K. Nooka United States | 36 | 3.4k 2.4× | 3.5k 2.6× | 2.9k 2.5× | 432 0.9× | 623 1.5× | 282 | 6.0k | ||
| Réda Bouabdallah France | 28 | 2.0k 1.4× | 1.5k 1.1× | 880 0.8× | 132 0.3× | 913 2.1× | 101 | 4.0k | ||
| Luis F. Porrata United States | 43 | 2.6k 1.9× | 1.7k 1.2× | 835 0.7× | 469 1.0× | 1.4k 3.3× | 211 | 5.4k | ||
| Nathalie Contentin France | 20 | 831 0.6× | 2.0k 1.4× | 610 0.5× | 169 0.3× | 520 1.2× | 49 | 2.8k | ||
| Mark Hertzberg Australia | 28 | 1.7k 1.2× | 1.1k 0.8× | 330 0.3× | 220 0.4× | 894 2.1× | 166 | 3.5k | ||
| M. Fevzi Özkaynak United States | 19 | 783 0.6× | 316 0.2× | 854 0.7× | 219 0.4× | 236 0.6× | 66 | 2.4k |
Countries citing papers authored by John Ellerton
Since
Specialization
Citations
This map shows the geographic impact of John Ellerton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Ellerton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Ellerton more than expected).
Fields of papers citing papers by John Ellerton
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John Ellerton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Ellerton. The network helps show where John Ellerton may publish in the future.
Co-authorship network of co-authors of John Ellerton
This figure shows the co-authorship network connecting the top 25 collaborators of John Ellerton. A scholar is included among the top collaborators of John Ellerton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Ellerton. John Ellerton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dahl, Douglas M., Theodore Karrison, M. Dror Michaelson, et al.. (2023). Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation. European Urology Oncology. 7(1). 83–90.
2.
Patel, Manish R., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. The Lancet Oncology. 19(1). 51–64.
3.
Apolo, Andrea B., John Ellerton, Jeffrey R. Infante, et al.. (2017). Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients. Annals of Oncology. 28. v300–v301.
4.
Apolo, Andrea B., John Ellerton, Jeffrey R. Infante, et al.. (2017). Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.. Journal of Clinical Oncology. 35(15_suppl). 4528–4528.
5.
Patel, Manish R., John Ellerton, Manish Agrawal, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible. Annals of Oncology. 27. vi267–vi267.
6.
Otterson, Gregory A., Miguel A. Villalona‐Calero, William J. Hicks, et al.. (2010). Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 16(8). 2466–2473.
7.
Niell, Harvey B., James E. Herndon, Antonius A. Miller, et al.. (2005). Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology. 23(16). 3752–3759.
8.
Silverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, et al.. (2005). Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.. Blood. 106(11). 2526–2526.
9.
Kornblith, Alice B., James E. Herndon, Lewis R. Silverman, et al.. (2002). Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 20(10). 2441–2452.
10.
Hoff, Paulo M., John Ellerton, Shaker R. Dakhil, et al.. (2000). Phase II Study of Intravenous CI-958 in Metastatic Colorectal Adenocarcinoma. American Journal of Clinical Oncology. 23(6). 602–604.
11.
Miller, Antonius A., James E. Herndon, Donna Hollis, et al.. (1995). Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.. Journal of Clinical Oncology. 13(8). 1871–1879.
12.
Wood, W. C., Ronald D. Hart, Anne Moore, et al.. (1994). Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. New England Journal of Medicine. 330(18). 1253–1259.
13.
Cooper, M. Robert, Keith Dear, O. Ross McIntyre, et al.. (1993). A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.. Journal of Clinical Oncology. 11(1). 155–160.
14.
Clamon, Gerald H., Matthew Perry, Howard Ozer, et al.. (1993). Interleukin-2 Activity in Patients With Extensive Small-Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B. JNCI Journal of the National Cancer Institute. 85(4). 316–320.
15.
Duggan, David B., María Teresa Santarelli, Kenneth W. Zamkoff, et al.. (1992). A Phase II Study of Recombinant Interleukin-2 With or Without Recombinant Interferon-?? in Non-Hodgkin??s Lymphoma. A Study of the Cancer and Leukemia Group B. Journal of Immunotherapy. 12(2). 115–122.
16.
Schilsky, Richard L., David Faraggi, Ann H. Korzun, et al.. (1991). Phase II study of echinomycin in patients with advanced breast cancer: A report of cancer and leukemia group B protocol 8641. Investigational New Drugs. 9(3). 269–272.
17.
Doll, D C, Stephen L. Graziano, John Ellerton, et al.. (1991). Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemotherapy and Pharmacology. 29(1). 71–74.
18.
Schulman, Philip, et al.. (1987). Phase II study of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia.. PubMed. 71(7-8). 755–7.
19.
Ellerton, John, et al.. (1980). Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group.. PubMed. 3(4). 369–74.
20.
Ellerton, John, G.A. Deveber, & Michael A. Baker. (1979). Erythroleukemia in a renal transplant recipient. Cancer. 43(5). 1924–1926.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Karel A. Dicke Breakdown of academic impact, for papers by Hani Hassoun Breakdown of academic impact, for papers by Stig Lenhoff Breakdown of academic impact, for papers by Stephen H. Petersdorf Breakdown of academic impact, for papers by Ajay K. Nooka Breakdown of academic impact, for papers by Réda Bouabdallah Breakdown of academic impact, for papers by Luis F. Porrata Breakdown of academic impact, for papers by Nathalie Contentin Breakdown of academic impact, for papers by Mark Hertzberg Breakdown of academic impact, for papers by M. Fevzi Özkaynak